Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy
of HLX04-O administered every 4 weeks in participants with wet age-related macular
degeneration (wAMD)